.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG16_Rozanolixizumab.Rozanolixizumab

Information

name:Rozanolixizumab
ATC code:L04AG16
route:subcutaneous
n-compartments2

Rozanolixizumab is a humanized monoclonal antibody targeting the neonatal Fc receptor (FcRn), used for the treatment of generalized myasthenia gravis (gMG) in adults. It functions by reducing IgG levels and is approved for clinical use in several regions.

Pharmacokinetics

Pharmacokinetic parameters were derived from clinical studies in adult patients with generalized myasthenia gravis following subcutaneous administration.

References

    Revisions

    Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos